Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in ...
The Senate failed to pass a massive spending bill on Thursday—which includes the rare pediatric PRV program but also funding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results